Special investor call on November 16, 2026, following presentation at the Society of Neuro-Oncology annual meeting

Alpha Tau Medical released interim results from its REGAIN study of Alpha DaRT in recurrent glioblastoma. The data were first presented over the weekend at the Society of Neuro-Oncology meeting in Philadelphia and discussed on a special investor call. Dr. Joshua Palmer, Professor of Radiation Oncology at Ohio State University and principal investigator of the study, presented the results. Of the 6 patients who have reached their response assessment, 5 achieved a complete response and 1 a partial response, for an objective response rate of 100%. All 8 patients treated to date remain alive, with median follow-up of approximately 7 months and survival ranging from 3 to 11.6 months.

No local failures so far, with one distant progression

Palmer called the absence of local recurrence "our most exciting component of the trial thus far." Patients with median follow-up of more than 6 months have had no recurrence at the treatment site, which he said exceeds what would be expected from historical controls. One patient has progressed, in a distant location. This was patient 1, who had a complete response at the 1-month and 3-month scans and developed a contralateral corpus callosum failure about 10 months after treatment, outside the radiation field.

Chief Medical Officer Dr. Robert Den said the pattern is itself a finding. "What we have seen in these first 6 patients is an alteration in the disease course, and a differentiation in terms of the recurrence patterns that we would typically expect to see in this population," he said, noting that the one recurrence was distant, which he described as atypical for this disease.

Palmer also tempered the response figures. He said that he does not want to "get too worried or excited only about, hey, look at how many CRs," and that the aim is to see those responses translate into patients "living closer to a year or longer." He described overall survival as probably the most critical endpoint in recurrent glioblastoma, noting that agents such as Avastin can delay progression but do not improve survival.

Benchmarks: what recurrent GBM patients typically do

Den framed the comparison. In recurrent glioblastoma, progression-free survival is typically 2 to 4 months and overall survival 6 to 9 months. Standard options, including lomustine, Avastin, surgery and re-irradiation, have not shown superiority over one another, with median survival around 9 months. He said that progression taking longer than 4 to 5 months, or survival approaching a year or more, would suggest a treatment is changing the disease course. Palmer said a median survival above 9 months in a small safety and feasibility study "would move the needle" and indicate a highly competitive therapy, while acknowledging that proving a survival benefit requires a large randomized study. He added that a strong showing in the recurrent setting would argue for moving the therapy earlier, into the upfront setting.

Palmer also said that having every patient alive at roughly 6 months is "incredible," given that some patients die within 3 to 6 months and median survival is typically 9 months.

Necrosis and pseudoprogression are the main imaging ambiguity

The most nuanced part of the data concerns radiographic changes around the implant. Two patients are being evaluated for necrosis or suspected necrosis, and it is too early to distinguish necrosis from progression in them. Patient 4, who had a partial response with a 58% decrease in tumor size, now shows a new area of nodular enhancement at a distance from the treated site and is undergoing biopsy to determine whether it is new tumor or radiation injury from overlap between the prior radiation field and Alpha DaRT. Patient 5 developed a wide area of enhancement at 3 months that is being treated as either treatment change or pseudoprogression and is awaiting confirmation scans. Patient 2 has ring enhancement around the seeds with a large necrotic center and is described as doing well on no additional therapy.

Two patients are on Avastin for necrosis. Palmer said one is completely unrelated to Alpha DaRT, an area within the prior radiation field that was already developing necrosis at the time of implant, and the other is probably related to Alpha DaRT. He said radiation treatment changes occur in more than half of patients who are followed beyond 6 months after re-irradiation, which is why Avastin is commonly used in the U.S. for necrosis rather than for oncologic purposes. Den stressed that all patients with necrosis are asymptomatic and said that quality of life is the second priority of recurrent GBM patients after survival.

On handling ambiguous cases in the interim analysis, Den said patients are considered progression-free unless they have progressed and are censored at last follow-up, which is the standard approach. He added that survival analysis is agnostic to the issue.

Safety: one Grade 3 event and two seizures

The primary endpoint of feasibility was met, with 100% of patients having all planned sources deployed and no unanticipated serious adverse events. There has been one Grade 3 serious adverse event, a seizure associated with paralysis, which resolved with rehabilitation and steroids; the patient is back to baseline. Palmer later said 2 patients had seizures within about 7 days of the procedure. He attributed them to radiation-related cerebral edema from a brisk immune response, as seen in high-dose radiosurgery, rather than to the seeds themselves. Patients are now premedicated and medicated for longer, and no further seizures have occurred. Every patient stay has been under 1 day....